Real-world evidence study evaluating the effectiveness, tolerability and utilization patterns of Vonoprazan in routine clinical practice across out-patient clinical setting in India
DOI:
https://doi.org/10.18203/2349-3933.ijam20263254Keywords:
Vonoprazan, Gastroesophageal reflux disease, Acid peptic disorders, Real-world evidence, Treatment effectivenessAbstract
Background: Gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) are two of the most common acid-related gastrointestinal conditions in India. They are associated with significant morbidity and impaired quality of life. Vonoprazan has demonstrated clinical efficacy in clinical trials and offers rapid and sustained acid suppression. However, there is still a dearth of empirical data on its therapeutic application and efficacy in Indian patients.
Methods: This multicentre, retrospective, observational real-world evidence study examined medical records from 8,325 patients prescribed Vonoprazan in outpatient settings across India during a 6-month period. Demographic details, indications, dose patterns, symptom improvement, treatment satisfaction, and safety outcomes were assessed using descriptive and comparative statistical methods.
Results: GERD (55.98%) and acid peptic disorders (APD; 33.07%) as diagnosed by the treating physicians were the most common indicators for Vonoprazan treatment. The majority of patients (93.14%) received 20 mg of Vonoprazan once daily. Symptoms improved significantly, with heartburn relief reported in 97.53% of patients and acid regurgitation improvement in 91.80%. Severe heartburn dropped from 44.06% at baseline to 1.93% after treatment (p<0.05), while acid regurgitation decreased from 31.95% to 6.56% (p<0.05). Overall treatment satisfaction was high, with 73.44% of patients reporting being extremely satisfied.
Conclusions: Vonoprazan demonstrated clinically meaningful real-world effectiveness, improvement in symptom control, favourable tolerability, and high patient satisfaction in Indian patients with GERD and other acid-related disorders, supporting its role as an effective therapeutic option in routine clinical practice.
References
Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-20.
Malfertheiner P, Chan FKL, McColl KEL. Peptic ulcer disease. Lancet. 2009;374(9699):1449-61.
Alqassab DF, Hasan MJ, AlSaadoon AM, AlMuqahwi AJ, AlAwadhi FA, Bahram SA, et al. Prevalence and risk factors of gastroesophageal reflux disease among adults attending primary healthcare in Bahrain. J Family Med Prim Care. 2024;13(12):5758-65.
Bhatia SJ, Reddy DN, Ghoshal UC, Jayanthi V, Abraham P, Choudhuri G, et al. Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2011;30(3):118-27.
Wang HY, Leena KB, Plymoth A, Hergens MP, Yin L, Shenoy KT, et al. Prevalence of gastro-oesophageal reflux disease and its risk factors in a community-based population in southern India. BMC Gastroenterol. 2016;16:36.
Rai RR, Gangadhar A, Mayabhate MM. Clinical profiling of patients with acid peptic disorders in India: a cross-sectional survey of clinicians. Int J Basic Clin Pharmacol. 2016;6(1):194-98.
Shanika LGT, Reynolds A, Pattison S, Braund R. Proton pump inhibitor use: systematic review of global trends and practices. Eur J Clin Pharmacol. 2023;79(9):1159-72.
Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267-85.
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases: a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.
El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14(4):447-60.
Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007;64(3):386-90.
Huang KZ, Weber HC. Potassium-competitive acid blockers and acid-related disorders. Curr Opin Endocrinol Diabetes Obes. 2024;31(3):107-14.
Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334-44.
Graham DY, Dore MP. Update on the use of Vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154(3):462-6.
Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231-8.
Mulford DJ, Leifke E, Hibberd M, Howden CW. The effect of food on the pharmacokinetics of the potassium competitive acid blocker vonoprazan. Clin Pharmacol Drug Dev. 2022;11:278-84.
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61-71.
Pattarapuntakul T, Wong T, Wetwittayakhlang P, Netinatsunton N, Keeratichananont S, Kaewdech A, et al. Efficacy of Vonoprazan vs. intravenous proton pump inhibitor in prevention of re-bleeding of high-risk peptic ulcers: a randomized controlled pilot study. J Clin Med. 2024;13:3606.
Geeratragool T, Kaosombatwattana U, Boonchote A, Chatthammanat S, Preechakawin N, Srichot J, et al. Comparison of Vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic haemostasis: a multicentre randomized noninferiority trial. Gastroenterology. 2024;167:778-87.e3.
Abe H, Tarasawa K, Hatta W, Koike T, Sato I, Ono Y, et al. Similar effect of Vonoprazan and oral proton pump inhibitors for preventing rebleeding in cases of upper gastrointestinal bleeding. Intern Med. 2024;63(7):911-8.
Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, et al. Randomised clinical trial: Vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240-51.
Oshima T, Sakurai J, Yamada M, Wakabayashi N, Toya Y, Tomita T, et al. Vonoprazan improves gastroesophageal reflux symptoms in patients with proton pump inhibitor-resistant non-erosive reflux disease. Dig Dis Sci. 2019;64(10):2917-22.
Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, et al. Efficacy of Vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95(2):156-61.
Tanabe T, Hori K, Kusunoki H, Kamiya T, Sato T, Yoshida S, et al. Clinical effectiveness of Vonoprazan in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a multicentre observational study. Esophagus. 2019;16(4):369-76.
Shinozaki S, Sakamoto H, Osawa H, Yano T, Lazaridis N, Yamamoto H. Timing and predictors for Vonoprazan dose escalation in refractory gastroesophageal reflux disease: a long-term observational study. Digestion. 2026;107(2):135-43.
Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-65.
El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243-50.
Wang HY, Leena KB, Plymoth A, Hergens MP, Yin L, Shenoy KT, et al. Prevalence of gastro-oesophageal reflux disease and its risk factors in a community-based population in southern India. BMC Gastroenterol. 2016;16:36.
Upadhyay R, Soni NK, Vora A, Saraf A, Haldipur D, Mukherjee D, et al. Association of Physicians of India consensus recommendations for Vonoprazan in management of acid peptic disorders. J Assoc Physicians India. 2025;73(2):68-77.
Mizuno H, Nishino M, Yamada K, Kamiyamamoto S, Hinoue Y. Efficacy of Vonoprazan for 48-week maintenance therapy of patients with healed reflux esophagitis. Digestion. 2020;101(4):411-21.
Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, et al. Maintenance for healed erosive esophagitis: phase III comparison of Vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550-61.
Oshima T, Arai E, Taki M, Kondo T, Tomita T, Fukui H, et al. Randomised clinical trial: Vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49(2):140-6.
Xiao Y, Zhang S, Dai N, Fei G, Goh KL, Chun HJ, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of Vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224-30.
Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, et al. Efficacy of long-term maintenance therapy with 10-mg Vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus. 2019;16(4):377-81.
Kojima Y, Takeuchi T, Sanomura M, Higashino K, Kojima K, Fukumoto K, et al. Does the novel potassium-competitive acid blocker Vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicentre prospective cross-sectional study. Digestion. 2018;97(1):70-5.
Wang HY, Leena KB, Plymoth A, Hergens MP, Yin L, Shenoy KT, et al. Prevalence of gastro-oesophageal reflux disease and its risk factors in a community-based population in southern India. BMC Gastroenterol. 2016;16:36.
Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-65.
Downloads
Published
How to Cite
Issue
Section
